Use of a combination (i.e., HIV combo) test that detects the HIV p24 antigen as well as antibodies to HIV provides an improvement in earlier detection compared to existing, sensitive, antibody-only immunoassays. The HIV combo test is increasingly becoming the standard screening technique used by healthcare authorities in many countries within the European Union, and there is an increasing trend among blood banks to use HIV combo assays. A new HIV combo assay from Siemens provides specificity comparable to current, leading antibody-only assays as well as the benefits of superior sensitivity and earlier HIV detection.
The Enzygnost® HIV Integral 4 Assay is Siemens' new combination assay that provides qualitative determination of HIV antibodies, including HIV-1, HIV-1 group O, and HIV-2, plus p24 antigen. Its high specificity and sensitivity enables clinicians to identify HIV infection and initiate treatment up to 14 days earlier than other assays currently on the market. The HIV Integral 4 Assay meets the specificity and sensitivity requirements of blood banks and other testing facilities. Siemens brings many years of experience, expertise, and leadership in HIV testing to the development of this new assay.
The Enzygnost HIV Integral 4 Assay has been validated on Siemens' widely used and highly reliable BEP2000 Advance®, BEP® III, and Quadriga BeFree® Systems.
for our complimentary webinar, "The Next Level of HIV Testing: Enhanced Diagnostics with the Antigen/Antibody Assay," to learn specifically how the HIV Combo test enhances early detection of HIV and improves safety and efficiency in transfusion medicine.
Enables earlier detection of HIV infection by 14 days compared to competitors
Features higher sensitivity and superior seroconversion performance compared to other assays on the market
International (English): +49 69 797 6602 You can call us Monday through Friday 8 am to 5 pm CET